LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations

AIMS: To report preliminary data on baseline serum calcitonin concentrations and associated clinical characteristics in a global population with type 2 diabetes before liraglutide or placebo randomization. METHODS: The ongoing LEADER trial has enrolled 9340 people with type 2 diabetes and at high ri...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Obes Metab
Autors principals: Daniels, G H, Hegedüs, L, Marso, S P, Nauck, M A, Zinman, B, Bergenstal, R M, Mann, J F E, Derving Karsbøl, J, Moses, A C, Buse, J B, Tuttle, R M
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2015
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4405040/
https://ncbi.nlm.nih.gov/pubmed/25656058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12444
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars